Trials / Completed
CompletedNCT00382148
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 6 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omalizumab | SC repeating dose |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-06-01
- First posted
- 2006-09-28
- Last updated
- 2009-12-15
- Results posted
- 2009-12-15
Source: ClinicalTrials.gov record NCT00382148. Inclusion in this directory is not an endorsement.